

### Remarks

Claims 1-5 are pending. Claim 1 has been amended. Support for the amendment can be found throughout the specification and originally filed claims. More specifically, the subject matter of claim 7 has been incorporated into claim 1.


### Election/Restriction

Claim 1 has been amended to define two species. It is believed the claim 1 satisfies the requirements set forth by the Examiner in his Election/Restriction rejection. The bisphosphonate is 2-(imidazol-1yl)-1-hydroxyethane-1,1-diphosphonic acid or a pharmacologically acceptable salt thereof. The cat K inhibitor is defined as N-[2-cyano-4-(2,2-dimethyl-propylamino)-pyrimidin-5-ylmethyl]-4-(4-methyl-piperazin-1-yl) benzamide or a pharmacologically acceptable salt thereof.

Entry of this Response is respectfully requested.

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7852

  
Oona A. Manzari  
Attorney for Applicants  
Reg. No. 48,152

Date: 12/19/07